Author details

Full Name

Christos Sotiriou

Affiliation

ORCID

Career Start Year

1995

Papers

330

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37532929	Pharmacological targeting of netrin-1 inhibits EMT in cancer.	Nature	2023
37608772	Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer	J Pathol	2023
37608771	Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.	J Pathol	2023
37923752	Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.	Nat Commun	2023
37919269	Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.	Nat Commun	2023
37733800	Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22-00.		2023
38086864	Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.	Nat Commun	2023
38056900	First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial.		2023
37479706	Obesity-associated changes in molecular biology of primary breast cancer.	Nat Commun	2023
36769602	Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges.		2023
37183094	Corrigendum to "Prognostic and predictive impact of beta-2 adrenergic receptor expression in HER2-positive breast cancer" [Clin Breast Cancer 2020; 20:262-73.e7].		2023
35017545	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer.	NPJ Breast Cancer	2022
36170624	Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse.	JCO Precision Oncology	2022
36354000	Improving Infinium MethylationEPIC data processing: re-annotation of enhancers and long noncoding RNA genes and benchmarking of normalization methods.	Epigenetics	2022
35882101	Timing evolution of lobular breast cancer through phylogenetic analysis.	EBioMedicine	2022
35927391	The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer.	NPJ Breast Cancer	2022
35790747	Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis.	NPJ Breast Cancer	2022
35728876	Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex.	Journal for ImmunoTherapy of Cancer	2022
35610260	Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials.	NPJ Breast Cancer	2022
35296682	Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.	npj Breast Cancer	2022
35043236	Incorporation of TILs in daily breast cancer care: how much evidence can we bear?	Virchows Arch	2022
34625860	Correction to: Tolerability and toxicity of trastuzumab or trastuzumabâ¿¿+â¿¿lapatinib in older patients: a subâ¿¿analysis of the ALTTO trial (BIG 2â¿¿06; NCCTG (Alliance) N063D).	Breast Cancer Res Treat	2022
34911733	Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer.	Cancer Discov	2022
34414109	Circulating Tumor DNA to Interrogate the Safety of Letrozole-Associated Controlled Ovarian Stimulation for Fertility Preservation in Breast Cancer Patients.	Frontiers in Oncology	2021
34183353	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative.	Cancer Discov	2021
34217971	Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations.	Breast	2021
34050190	Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer.	npj Breast Cancer	2021
33947930	The genomic landscape of carcinomas with mucinous differentiation.	Sci Rep	2021
34198891	HER2-Low Breast Cancer: Molecular Characteristics and Prognosis.	Cancers	2021
33721561	70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.	Lancet Oncol	2021
34321278	Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.	Clinical Cancer Research	2021
33152119	STAT3 activation in HER2-positive breast cancers: Analysis of data from a large prospective trial.	International Journal of Cancer	2021
32951084	Tolerability and toxicity of trastuzumab or trastuzumabâ¿¿+â¿¿lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).	Breast Cancer Res Treat	2021
33328637	Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis.	Nature	2021
34465600	Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer.	Clin Cancer Res	2021
34548493	FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.	npj Breast Cancer	2021
34548320	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis.	Clin Cancer Res	2021
34711609	Heterogeneity of Circulating Tumor Cell-Associated Genomic Gains in Breast Cancer and Its Association with the Host Immune Response.	Cancer Res	2021
35122061	NR2F2 controls malignant squamous cell carcinoma state by promoting stemness and invasion and repressing differentiation.	Nature Cancer	2021
34362344	Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.	BMC Cancer	2021
35121941	Downregulation of the FTO mA RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors.	Nature Cancer	2021
32943456	Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer.	Clin Cancer Res	2020
32428688	Late effects of adjuvant chemotherapy adumbrate dormancy complexity in breast cancer.	Breast	2020
31904863	Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer.	International Journal of Cancer	2020
32129476	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.	J Pathol	2020
31839676	Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.	British Journal of Cancer	2020
32056259	The 2019 World Health Organization classification of tumours of the breast.	Histopathology	2020
32229175	Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer.	Clinical Breast Cancer	2020
31665482	Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach.	Journal of the National Cancer Institute	2020
33303745	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells.	Nature Communications	2020